We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Persistent Airflow Limitation Found Common in Severe Asthma

By HospiMedica staff writers
Posted on 15 Jan 2008
A new study has found that persistent airflow limitation (PAFL) is prevalent in patients with severe or difficult-to-treat asthma and is associated with identifiable risk factors such as age, gender, and duration of disease.

Researchers at Genentech (San Francisco, CA, USA) conducted a prospective, observational three-year study that included 1,017 adult patients aged 18 or older with severe or difficult-to-treat asthma. More...
The purpose of the study was to evaluate a wide range of potential risk factors in these high-risk asthma patients. Six hundred twelve (60%) had PAFL, defined as post-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) of 70% or lower at two annual consecutive visits. The remaining 405 patients had a post-bronchodilator FEV1/FVC ratio between 75% and 85%, and made up the no-PAFL group.

Study findings identified several factors independently associated with PAFL, including older age, male gender, black ethnicity, aspirin sensitivity, a longer duration of disease, and current or past smoking. Consistent with other studies, PAFL was also associated with more severe asthma. Protective factors for PAFL included Hispanic ethnicity, a college education or advanced degree, a family history of atopic dermatitis, having a pet or pets in the home, and reported dust sensitivity. Rates of urgent health care utilization, however, were similar between patients with and without PAFL. The study was published in the December 2007 issue of the journal Chest.

"The findings help define which patients are at risk for PAFL, and the factors that may prevent or reduce progression into a predominantly irreversible form,” concluded lead author Dr. June H. Lee, M.D., and colleagues.

Asthma is defined as a chronic inflammatory disease of the airways and characterized by reversible airflow obstruction. However, for many patients with asthma, the obstruction fails to reverse after treatment. The structural changes associated with asthma include increased airway smooth-muscle mass, mucous gland and goblet-cell hyperplasia, and thickening of the reticular basement membrane. Currently, the relationship between airway physical changes and the degree of PAFL obstruction is not well understood.


Related Links:
Genentech

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.